MXCT vs INCY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
INCY Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Incyte Genomics Inc (INCY) driven by superior Valuation, Growth & Margin while MXCT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, MXCT trades at N/M Forward P/E with -85.5% operating margin (+48.7% YoY revenue) versus INCY at 13.3x Forward P/E and 32.2% operating margin (+14.0% YoY). In options structure, MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against INCY sits in CONSOLIDATION (37th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | INCY Revenue | MXCT Op. Margin | INCY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $1.88B | N/A | 6.9% | INCY |
| FY2019 | $10M | $2.16B | -93.7% | 18.6% | INCY |
| FY2020 | $20M | $2.67B | -71.6% | -9.9% | INCY |
| FY2021 | $20M | $2.99B | -84.3% | 19.6% | INCY |
| FY2022 | $30M | $3.39B | -95.2% | 17.1% | INCY |
| FY2023 | $20M | $3.70B | -247.7% | 16.8% | INCY |
| FY2024 | $20M | $4.24B | -230.5% | 1.4% | INCY |
| FY2025 | $20M | $5.14B | -247.6% | 29.5% | INCY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MXCT | INCY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $132.2M | $23.6B | Larger Scale | INCY |
| Trailing P/E Ratio Valuation | N/M | 59.1x | Lower Multiple | INCY |
| Forward P/E Ratio Valuation | N/M | 13.3x | Lower Multiple | INCY |
| Revenue Growth (YoY) Growth | +48.7% | +14.0% | Higher Growth | MXCT |
| Operating Margin (TTM) Profitability | -85.5% | 32.2% | Higher Margin | INCY |
| Net Profit Margin Profitability | -81.4% | 6.7% | Higher Margin | INCY |
| Return on Equity (ROE) Capital Efficiency | -16.9% | 7.8% | Higher ROE | INCY |
| 52-Week Range Position Momentum | 63% ($1โ$2) | 58% ($89โ$133) | Stronger Trend | MXCT |
| Beta / 30D Volatility Risk Regime | 1.19ฮฒ ยท 96% Vol | 0.30ฮฒ ยท 31% Vol | Lower Realized Risk | INCY |
| Unified Institutional Score Composite Signal | 41.7 / 100 (SELL) | 54.6 / 100 (HOLD) | Higher Composite | INCY |